Sodium Chloride Intravenous Infusion BP 0.9% w/v
Sponsors
Merck Sharp & Dohme LLC, Alnylam Pharmaceuticals Inc.
Conditions
Pneumococcal infectionRenal cell carcinomaTransthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
Phase 3
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (KEYNOTE-564)
Active, not recruitingCTIS2022-501251-81-00
Start: 2017-06-08Target: 350Updated: 2026-01-27
A Phase 3, Randomized, Double-blind, Active Comparator-controlled Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Pneumococcal Vaccine-naïve Adults 18 to 64 years of Age With Increased Risk for Pneumococcal Disease
CompletedCTIS2022-502791-22-01
Start: 2023-05-17End: 2024-02-06Target: 100Updated: 2024-02-29
A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Patisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with Cardiomyopathy)
CompletedCTIS2023-508364-29-00
Start: 2019-11-22End: 2025-05-15Target: 79Updated: 2025-08-14